Long accused of “dumping” product into overseas markets to the detriment of foreign competitors, Canadian licensed cannabis producers may at last be punished for the alleged practice.
Trade officials in Israel are considering imposing new tariffs on Canadian medical cannabis in response to formal complaints from domestic growers that LPs are violating World Trade Organization rules.
A duty would raise the cost of selling into a market that took about 40 metric tons, or 15%, of Canada’s flower exports in 2025. A decision was still pending as of Wednesday.
Though cannabis producers in Portugal and Australia have also complained of unfair competition from artificially cheap Canadian cannabis, Israel is so far the only country to open a formal case.
In the meantime, Canadian trade officials say they are monitoring the situation as competition for major export markets like Germany heats up – and as potential rule changes that could disrupt the global cannabis trade loom.
What is cannabis ‘dumping’?
On Oct. 22, Israel’s commissioner for trade levies, Danny Tal, named four alleged offending exporters:
- Cronos GrowCo, a Kingsville, Ontario, greenhouse grower half owned and controlled by Toronto-based Cronos Group. Tal says it supplied more than 60% of Canadian exports to Israel.
- Koots Canna, a British Columbia grower.
- Cielo Verde Quebec.
- 2323414 Alberta, a wholly owned subsidiary of Calgary, Alberta-based CannaPharmaRx.
The four supply about 70% of the cannabis Israel imports from Canada, Israeli officials estimate.
Tal estimated the dumping margin at about 125% when he reopened the case Aug. 5. He compared an export price of 4.43 shekels ($1.42) a gram with a Canadian price of about 10 shekels ($3.21).
Subscribe to the MJBiz Factbook
Exclusive industry data and analysis to help you make informed business decisions and avoid costly missteps. All the facts, none of the hype.
What you will get:
- Monthly and quarterly updates, with new data & insights
- Financial forecasts + capital investment trends
- State-by-state guide to regulations, taxes & market opportunities
- Annual survey of cannabis businesses
- Consumer insights
- And more!
The complainants, Trichom and Evergreen Solomon Pharma, claim18 Israeli growers have stopped operating. Meanwhile, cannabis imports from Canada grew 42% in 2025 to about 30.5 metric tons.
A Cronos spokesperson said the company, which has seen revenue increase thanks to exports, “does not engage in dumping.”
Koots Canna declined to comment. Cielo Verde and CannaPharmaRx did not respond to requests for comment.
Arie Reich, a trade lawyer at Weiss Porat & Co. who represents the Israeli growers, told MJBizDaily the new complaint is “a last effort to save the industry.”
Israel approved duties once before. In April 2025, after finding dumping margins of 63% to 554%, the economy minister signed off on duties of up to 165%.
However, Finance Minister Bezalel Smotrich blocked them later that month after the Health Ministry and Competition Authority warned of higher prices for patients.
Have Canadian licensed cannabis producers ever been punished for ‘dumping’?
Under World Trade Organization rules, dumping – or exporting a product for less than it sells for at home – is banned. An offended country can legally add punitive tariffs if it shows the imports injured its own industry.
Canada has long been the world’s largest cannabis exporter. Suspicions that companies have been swamping overseas markets with surplus product have swirled for nearly as long.
Big Canadian producers send surplus flower, “most of the time very old flower, which is cultivated for recreation,” to Portugal for GMP processing, Miguel Nobrega Gouveia, CEO of Master Med Cann, a Portuguese medical cannabis grower, told MJBizDaily.
The cannabis is then “dumped into the other EU markets, especially Germany,” he said. In response, Portuguese companies are forced to sell below cost in order to compete, he said.
But overseas cultivators are unlikely to find satisfaction. Nan-Maree Schoerie, CEO of Australian grower ECS Botanics told MJBizDaily it’s “almost impossible to prove dumping based on the definitions.”
Nevertheless, Rachael Dolan, a spokesperson for Global Affairs Canada, the said the agency “remains concerned” about the dumping accusations.
Deepak Anand, vice president of government affairs at Village Farms International, a Nasdaq-listed cannabis producer not involved in the case, said Global Affairs “has engaged well on the trade law side.”
“What’s missing is an export strategy,” he said. And potentially at risk are other much more lucrative markets – without which Canadian cannabis production can’t exist as-is.
“Cannabis is now a real Canadian export, and Germany alone is worth hundreds of millions of dollars a year,” Anand added.
Where is Canadian cannabis going?
Germany imported 203 metric tons of cannabis in 2025, according to federal drug regulator BfArM. About 93 tons came from Canada – and prices are dropping.
The declared price of Canadian flower shipped to Germany dropped from $3.95 Canadian ($2.80) a gram in March 2025 to $2.93 Canadian ($2.08) in February 2026, Statistics Canada trade data shows.
Germany’s pharmaceutical cannabinoid industry association, BPC, hasn’t called for trade measures, board chair Antonia Menzel said.
Import prices fell mainly because imports are growing from a range of countries, she said.
In Europe, an anti-dumping case would go to the European Commission and requires the backing of companies with at least 25% of EU production.
Can European producers survive Canadian cannabis exports?
In the long run, Canadian cannabis producers face a bigger potential obstacle than tariffs in response to dumping. There’s a growing unwillingness in Europe to accept cannabis from Canada over European Union Good Manufacturing Practices-compliant supply grown locally.
Currently, flower grown to a standard for medicinal plants, known as GACP, can be dried, trimmed, tested and packed at an EU-GMP site. A German importer can then buy it as EU-GMP flower.
On June 8, the health authority in the German state of Hesse published guidance that treats controlled drying as a GMP step. The guidance also doubts that GACP flower can travel long distances and go through later processing without losing quality.
If other regulators follow, flower grown for Canada’s recreational market would have no path into German pharmacies.
Australia takes the opposite approach. Its Therapeutic Goods Administration does not require GMP approval for the site that grows and dries imported flower if later steps such as irradiation and packing happen under GMP.
That makes Australia a destination for GACP flower, said ECS Botanics’ 5Schoerie, who added those standards a bigger problem than dumping.


